Adaptive Biotechnologies Corp (NASDAQ: ADPT) kicked off on Tuesday, up 6.08% from the previous trading day, before settling in for the closing price of $5.26. Over the past 52 weeks, ADPT has traded in a range of $2.28-$5.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.46%. While this was happening, its average annual earnings per share was recorded 22.02%. With a float of $142.33 million, this company’s outstanding shares have now reached $145.08 million.
Let’s determine the extent of company efficiency that accounts for 709 employees. In terms of profitability, gross margin is 49.93%, operating margin of -109.49%, and the pretax margin is -126.53%.
Adaptive Biotechnologies Corp (ADPT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adaptive Biotechnologies Corp is 3.49%, while institutional ownership is 97.12%. The most recent insider transaction that took place on Aug 22 ’24, was worth 121,079. In this transaction SVP and General Counsel of this company sold 26,922 shares at a rate of $4.50, taking the stock ownership to the 139,365 shares. Before that another transaction happened on Aug 22 ’24, when Company’s Officer proposed sale 26,922 for $4.50, making the entire transaction worth $121,079.
Adaptive Biotechnologies Corp (ADPT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 22.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.60% during the next five years compared to -32.91% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Take a look at Adaptive Biotechnologies Corp’s (ADPT) current performance indicators. Last quarter, stock had a quick ratio of 3.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Looking closely at Adaptive Biotechnologies Corp (NASDAQ: ADPT), its last 5-days average volume was 1.03 million, which is a drop from its year-to-date volume of 1.41 million. As of the previous 9 days, the stock’s Stochastic %D was 90.70%. Additionally, its Average True Range was 0.33.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 92.34%, which indicates a significant decrease from 99.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.09% in the past 14 days, which was lower than the 71.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.74, while its 200-day Moving Average is $3.91. However, in the short run, Adaptive Biotechnologies Corp’s stock first resistance to watch stands at $5.75. Second resistance stands at $5.92. The third major resistance level sits at $6.25. If the price goes on to break the first support level at $5.25, it is likely to go to the next support level at $4.92. Now, if the price goes above the second support level, the third support stands at $4.75.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
The company with the Market Capitalisation of 822.89 million has total of 147,472K Shares Outstanding. Its annual sales at the moment are 170,280 K in contrast with the sum of -225,250 K annual income. Company’s last quarter sales were recorded 43,190 K and last quarter income was -46,220 K.
